Nivolumab With Gemcitabine Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients

  • STATUS
    Recruiting
  • End date
    Nov 2, 2024
  • participants needed
    388
  • sponsor
    Universität des Saarlandes
Send
Updated on 2 February 2021
See if I qualify
hodgkin's disease
rituximab
cell transplantation
anthracyclines
nivolumab
b-cell lymphoma
aggressive non-hodgkin's lymphoma

Summary

This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in case of B-cell lymphoma

Description

International, multicentre, randomised, open-label, treatment optimisation study, preceded by safety run-in phases conducted for B-cell and T-cell lymphoma separately.

Details
Condition Lymphoma, Non-Hodgkin's Lymphoma, non-hodgkin's lymphoma (nhl)
Treatment Rituximab, Gemcitabine, Oxaliplatin, Nivolumab
Clinical Study IdentifierNCT03366272
SponsorUniversität des Saarlandes
Last Modified on2 February 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Non-Hodgkin's Lymphoma or Lymphoma?
Do you have any of these conditions: non-hodgkin's lymphoma (nhl) or Lymphoma or Non-Hodgkin's Lymphoma?
Do you have any of these conditions: Lymphoma or non-hodgkin's lymphoma (nhl) or Non-Hodgkin's Lymphoma?
Do you have any of these conditions: non-hodgkin's lymphoma (nhl) or Lymphoma or Non-Hodgkin's Lymphoma?
Do you have any of these conditions: Lymphoma or non-hodgkin's lymphoma (nhl) or Non-Hodgkin's Lymphoma?
patients with first relapse or progression of an aggressive Non-Hodgkin's lymphoma
all patient >65 years of age or older than 18 years if HCT-CI score > 2 or patients who underwent prior autologous stem cell transplantation and are not eligible for allogeneic stem cell Transplantation
All risk groups (IPI 0 to 5)
Diagnosis of aggressive Non-Hodgkin's lymphoma, based on an excisional biopsy of a lymph node or on an appropriate sample of a lymph node or of an extranodal involvement at initial diagnosis or relapse or Progression. The entities treated in the study will be based on the WHO 2017 classification
ECOG 0 - 2
only one prior chemotherapy regimen including an anthracycline. The last cytotoxic drug must be given at least four weeks before entering the study. Rituximab must be part of the first-line regimen in case of B-cell lymphoma. Patients may have received prior radiation therapy as part of their first-line therapy
Men who are sexually active with women of childbearing potential (WOCBP) must not father a child during and up to 6 months after GemOx and up to 12 months after Rituximab and/or Nivolumab. They are advised to do cryoconservation of sperm prior to treatment
Written informed consent of the patient
Patient must be covered by social security system

Exclusion Criteria

Already initiated lymphoma therapy after first relapse or progression
Serious accompanying disorder or impaired organ function
WBC < 2.5 G/l, Neutrophils < 2 G/l, Platelets < 100 G/l
Prolongation of QTc interval > 450 ms, demonstrated in one electrocardiogram (done as triplicate). This does not apply for patients with a block of the right and/or left bundle branch
Family history for Long QT-Syndrome
active, known or suspected autoimmune disease
no requirement for immunosuppressive doses of systemic corticosteroids
Chronic active hepatitis B or C
HIV-infection
Patients with a severe immunodeficiency
Previous therapy with Nivolumab,Gemcitabine or Oxaliplatin
Patients with a "currently active" second malignancy other than non-melanoma skin cancer
CNS involvement of lymphoma
Persistent neuropathy grade >2
Pregnancy or breast-feeding women
Women of childbearing potential
Active serious infections not controlled by oral and/or intravenous antibiotics or anti-fungal medication
Any medical condition which in the opinion of the investigator places the subject at an unacceptably high risk for toxicities
Lymphomas other than those listed in the inclusion criteria notably indolent lymphoma, Mantle cell lymphoma, Burkitt lymphoma, adult T-cell leukemia/lymphoma
Persons not able to understand the impact, nature, risks and consequences of the trial (including language barrier)
Persons not agreeing to the transmission of their pseudonymous data
Persons depending on sponsor or investigator
Persons from highly protected Groups
Allergies and Adverse Drug Reaction History to study drug components
Participation in another clinical trial with drug intervention within 4 weeks prior to start of the first cycle and during the study. However, participation in a clinical trial of firstline therapy of lymphoma is allowed
Clear my responses
Read more

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

hodgkin's disease
rituximab
cell transplantation
anthracyclines
nivolumab
b-cell lymphoma
aggressive non-hodgkin's lymphoma

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note